Alzheimer s disease

LE WE PMID CA

Alzheimer s disease

114

Alzheimer Erkrankung

27 Hydroxycholesterol

Aids

Aluminum

Alzheimer s disease

Amygdala

Amyloid angiopathy

Amyloid precursor protein

Amyloidosis

Amyotrophic lateral sclerosis

Antibodies (catalytic)

Antiinflammatory compounds

Apolipoprotein E4

Aripiprazole

Autophagy

BACE1

Bapineuzumab ttAmyloidBeta

Beclin1

Biomarker (BASKET)

Biomembranes (BASKET)

Borreliosis

CNS (MRS)

CNS (MRT)

CNS (PET)

CNS (Stroke BASKET)

Cystatin C

Dementia (frontotemporal)

Donepezil

ERS UFR (Toxikologie)

Frontotemporal lobar degeneration

GADD153 CHOP

Galantamine

gamma Secretase

Genetics (Gene expression endophenotype)

History of medicine

Imaging (Molecular)

Insulin degrading enzyme

Kluver Bucy syndrome

Leptin

Lewy body

Lipid peroxide

Lipid rafts and membrane microdomains

LRP1

Maillard reaction

Melatonin

Memantine

MGAT3

Mitochondria (BASKET)

Mitochondria (Dysfunction)

Mitochondria (Mitochondriopathy)

Mitophagy

MRT (functional fMRT)

Multiple sclerosis

NADPH oxidase

Nervous system (Neurodegeneration)

Neuron (BASKET)

Neurovascular unit

Niemann Pick s disease C

Paradontosis

Parkinson s disease

Pin1

Prions and associated diseases

Retinoids

Rivastigmin

Septum (Neurophysiology)

Sirtuin

SORL1

Spirochaete

Statin

Structure det. tissue level to single molecule localization

Sulfatides

Synuclein

TDP43

Testosterone

Tissue transglutaminase

Treponemas

2005 1	Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. [16081444] BMJ 331(7512): 321-7 (2005)
2005 2	Treatments for Alzheimer disease. [16004170] South Med J 98(6): 628-35 (2005)
2001 3	Biological and genetic markers of sporadic Alzheimer's disease. [11332200] Acta Med Okayama 55(2): 55-63 (2001)
2009 4	Mitochondrial Drugs for Alzheimer Disease. [20657666] Pharmaceuticals (Basel) 2(3): 287-298 (2009)
1999 5	Diagnosis, management, and treatment of Alzheimer disease: a guide for the internist. [10219924] Arch Intern Med 159(8): 789-98 (1999)
1997 6	The genetics and pathophysiology of Alzheimer's disease. [9366805] J Intern Med 242(4): 281-4 (1997)
2009 7	Alzheimer disease: time to improve its diagnosis and treatment. [19122111] Cleve Clin J Med 76(1): 49-58 (2009)
2008 8	Insular Alzheimer disease pathology and the psychometric correlates of mortality. [18540156] Cleve Clin J Med 75 Suppl 2(): S97-9 (2008)
2008 9	Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. [18686744] Clin Interv Aging 3(2): 211-25 (2008)
2007 10	Pathogenesis of Alzheimer's disease. [18044185] Clin Interv Aging 2(3): 347-59 (2007)
2007 11	Rivastigmine in the treatment of Alzheimer's disease: an update. [18044073] Clin Interv Aging 2(1): 17-32 (2007)
2007 12	Pharmacologic management of neuropsychiatric symptoms of Alzheimer disease. [18020111] Can J Psychiatry 52(10): 630-46 (2007)
2007 13	Pharmacotherapy of Alzheimer disease. [18020110] Can J Psychiatry 52(10): 620-9 (2007)
2007 14	Trials and tribulations of evidence-based medicine: the case of Alzheimer disease therapeutics. [18020109] Can J Psychiatry 52(10): 617-9 (2007)
2004 15	GABAergic function in Alzheimer's disease: evidence for dysfunction and potential as a therapeutic target for the treatment of behavioural and psychological symptoms of dementia. [15362248] Can J Psychiatry 49(7): 439-53 (2004)
2007 16	Changing the course of Alzheimer's disease: anti-amyloid disease-modifying treatments on the horizon. [17599166] Prim Care Companion J Clin Psychiatry 9(1): 32-41 (2007)
1999 17	The neurobiology and pharmacotherapy of Alzheimer's disease. [9990552] J Neuropsychiatry Clin Neurosci 11(1): 19-31 (1999)
2000 18	Neurobiological basis of behavioral and psychological symptoms in dementia of the Alzheimer type. [11145458] Psychiatry Clin Neurosci 54(6): 611-20 (2000)
2001 19	Cellular and molecular mechanisms of estrogen regulation of memory function and neuroprotection against Alzheimer's disease: recent insights and remaining challenges. [11390632] Learn Mem 8(3): 121-33 (2001)
2009 20	Update on the use of memantine in Alzheimer's disease. [19557118] Neuropsychiatr Dis Treat 5(): 237-47 (2009)
2008 21	Cost-effectiveness of drug therapies for Alzheimer's disease: A brief review. [18830441] Neuropsychiatr Dis Treat 4(3): 549-55 (2008)
2007 22	Memantine: efficacy and safety in mild-to-severe Alzheimer's disease. [19300557] Neuropsychiatr Dis Treat 3(2): 245-58 (2007)
2007 23	Progress update: Pharmacological treatment of Alzheimer's disease. [19300586] Neuropsychiatr Dis Treat 3(5): 569-78 (2007)
2006 24	Sorting through the cell biology of Alzheimer's disease: intracellular pathways to pathogenesis. [17015224] Neuron 52(1): 15-31 (2006)
2006 25	A hundred years of Alzheimer's disease research. [17015223] Neuron 52(1): 3-13 (2006)
2004 26	Deciphering the molecular basis of memory failure in Alzheimer's disease. [15450169] Neuron 44(1): 181-93 (2004)
1996 27	Mechanisms of neuronal degeneration in Alzheimer's disease. [8630250] Neuron 16(5): 921-32 (1996)
2009 28	The role of abnormal mitochondrial dynamics in the pathogenesis of Alzheimer's disease. [19393022] J Neurochem 109 Suppl 1(): 153-9 (2009)
2007 29	Potential mechanisms contributing to sulfatide depletion at the earliest clinically recognizable stage of Alzheimer's disease: a tale of shotgun lipidomics. [17986152] J Neurochem 103 Suppl 1(): 171-9 (2007)
2010 30	Tau oligomers and aggregation in Alzheimer's disease. [19943854] J Neurochem 112(6): 1353-67 (2010)
2009 31	Cholesterol metabolism and transport in the pathogenesis of Alzheimer's disease. [20050287] J Neurochem 111(6): 1275-308 (2009)
2009 32	The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. [19457065] J Neurochem 110(4): 1129-34 (2009)
2007 33	Alzheimer's disease: the lipid connection. [17986151] J Neurochem 103 Suppl 1(): 159-70 (2007)
2006 34	Alois Alzheimer and Alzheimer's disease: a centennial perspective. [17076655] J Neurochem 99(3): 708-10 (2006)
2006 35	Do axonal defects in tau and amyloid precursor protein transgenic animals model axonopathy in Alzheimer's disease? [16787410] J Neurochem 98(4): 993-1006 (2006)
2006 36	Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics. [16805778] J Neurochem 97(6): 1700-25 (2006)
2006 37	Septal networks: relevance to theta rhythm, epilepsy and Alzheimer's disease. [16405497] J Neurochem 96(3): 609-23 (2006)
2006 38	Amyloid precursor protein-mediated free radicals and oxidative damage: implications for the development and progression of Alzheimer's disease. [16305625] J Neurochem 96(1): 1-13 (2006)
2006 39	Neuronal protection by sirtuins in Alzheimer's disease. [16219030] J Neurochem 96(2): 305-13 (2006)
2004 40	Non-steroidal anti-inflammatory drugs (NSAIDs) in Alzheimer's disease: old and new mechanisms of action. [15485484] J Neurochem 91(3): 521-36 (2004)
2004 41	A modified beta-amyloid hypothesis: intraneuronal accumulation of the beta-amyloid peptide--the first step of a fatal cascade. [15485483] J Neurochem 91(3): 513-20 (2004)
2003 42	Proteomics in Alzheimer's disease: insights into potential mechanisms of neurodegeneration. [12950441] J Neurochem 86(6): 1313-27 (2003)
1999 43	Alzheimer's disease and the amyloid beta protein: What is the role of amyloid? [10428038] J Neurochem 73(2): 443-9 (1999)
1997 44	An etiological role of amyloidogenic carboxyl-terminal fragments of the beta-amyloid precursor protein in Alzheimer's disease. [9109502] J Neurochem 68(5): 1781-91 (1997)
2009 45	Mechanism-based treatments for Alzheimer's disease. [19585951] Dialogues Clin Neurosci 11(2): 159-69 (2009)
2009 46	Imaging in Alzheimer's disease. [19585954] Dialogues Clin Neurosci 11(2): 191-9 (2009)
2009 47	Biological markers for early detection and pharmacological treatment of Alzheimer's disease. [19585950] Dialogues Clin Neurosci 11(2): 141-57 (2009)
2009 48	Novel strategies for the prevention of dementia from Alzheimer's disease. [19585948] Dialogues Clin Neurosci 11(2): 129-34 (2009)
2009 49	Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention. [19585947] Dialogues Clin Neurosci 11(2): 111-28 (2009)
2007 50	Frontotemporal dementia to Alzheimer's disease. [17726914] Dialogues Clin Neurosci 9(2): 153-60 (2007)
2003 51	The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. [14530799] CNS Drug Rev 9(3): 275-308 (2003)
2002 52	Imaging amyloid-beta deposits in vivo. [12218409] J Cereb Blood Flow Metab 22(9): 1035-41 (2002)
2009 53	Current Challenges for the Early Detection of Alzheimer's Disease: Brain Imaging and CSF Studies. [20076796] J Clin Neurol 5(4): 153-66 (2009)
2007 54	The involvement of astrocytes and kynurenine pathway in Alzheimer's disease. [18201952] Neurotox Res 12(4): 247-62 (2007)
2007 55	Glial cell dysregulation: a new perspective on Alzheimer disease. [18201950] Neurotox Res 12(4): 215-32 (2007)
2002 56	Involvement of Maillard reactions in Alzheimer disease. [12829400] Neurotox Res 4(3): 191-209 (2002)
2003 57	The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development. [12805474] J Pharmacol Exp Ther 306(3): 821-7 (2003)
2009 58	Nicotinic acetylcholine receptor signalling: roles in Alzheimer's disease and amyloid neuroprotection. [19293145] Pharmacol Rev 61(1): 39-61 (2009)
2002 59	Amyloid precursor protein, presenilins, and alpha-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer's disease. [12223532] Pharmacol Rev 54(3): 469-525 (2002)
1997 60	From molecular structure to Alzheimer therapy. [9268083] Jpn J Pharmacol 74(3): 225-41 (1997)
2006 61	The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease. [16409879] Health Technol Assess 10(1): iii-iv, ix-xi, 1-160 (2006)
1999 62	Insights into the neurodegenerative process of Alzheimer's disease: a role for mononuclear phagocyte-associated inflammation and neurotoxicity. [10204569] J Leukoc Biol 65(4): 416-27 (1999)
1999 63	Inflammation of the brain in Alzheimer's disease: implications for therapy. [10204568] J Leukoc Biol 65(4): 409-15 (1999)
2008 64	Alzheimer's disease is type 3 diabetes-evidence reviewed. [19885299] J Diabetes Sci Technol 2(6): 1101-13 (2008)
2005 65	Molecular mechanisms initiating amyloid beta-fibril formation in Alzheimer's disease. [15933761] Acta Biochim Pol 52(2): 417-23 (2005)
2000 66	Alzheimer's disease: its origin at the membrane, evidence and questions. [11310972] Acta Biochim Pol 47(3): 725-33 (2000)
2010 67	Plasma beta-amyloid as potential biomarker of Alzheimer disease: possibility of diagnostic tool for Alzheimer disease. [20567751] Mol Biosyst 6(10): 1760-6 (2010)
2009 68	Metallo-complex activation of neuroprotective signalling pathways as a therapeutic treatment for Alzheimer's disease. [19156258] Mol Biosyst 5(2): 134-42 (2009)
2001 69	Molecular and cell biological aspects of Alzheimer disease. [11721879] J Hum Genet 46(11): 609-18 (2001)
1996 70	Biological markers for the clinical diagnosis of Alzheimer's disease. [8875763] Tohoku J Exp Med 179(2): 65-79 (1996)
1994 71	Alzheimer's disease and beta-amyloid. [7761982] Tohoku J Exp Med 174(3): 181-303, A1-3 (1994)
1994 72	Inflammatory response in Alzheimer's disease. [7539162] Tohoku J Exp Med 174(3): 295-303 (1994)
2006 73	Alzheimer's disease: psychopathology, medical management and dental implications. [16946428] J Am Dent Assoc 137(9): 1240-51 (2006)
2005 74	Fatty acid oxidation in the pathogenesis of Alzheimer's disease. [15855630] Am J Pathol 166(5): 1283-9 (2005)
1996 75	The Golgi apparatus and the pathogenesis of Alzheimer's disease. [8579097] Am J Pathol 148(2): 355-60 (1996)
2007 76	Mitoenergetic failure in Alzheimer disease. [16807300] Am J Physiol Cell Physiol 292(1): C8-23 (2007)
2004 77	Alzheimer disease: mechanistic understanding predicts novel therapies. [15096334] Ann Intern Med 140(8): 627-38 (2004)
2003 78	Alzheimer disease: current concepts and emerging diagnostic and therapeutic strategies. [12614093] Ann Intern Med 138(5): 400-10 (2003)
2008 79	Retromer sorting: a pathogenic pathway in late-onset Alzheimer disease. [18332244] Arch Neurol 65(3): 323-8 (2008)
2006 80	Therapeutic approaches to Alzheimer's disease. [17018549] Brain 129(Pt 11): 2840-55 (2006)
2009 81	The molecular biology of senile plaques and neurofibrillary tangles in Alzheimer's disease. [20054780] Folia Neuropathol 47(4): 289-99 (2009)
2006 82	Plaques and tangles and the pathogenesis of Alzheimer's disease. [16565925] Folia Neuropathol 44(1): 1-11 (2006)
2005 83	The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease. [15864339] J Clin Invest 115(5): 1121-9 (2005)
1999 84	The cholinergic hypothesis of Alzheimer's disease: a review of progress. [10071091] J Neurol Neurosurg Psychiatry 66(2): 137-47 (1999)
2004 85	Interactions between beta-amyloid and central cholinergic neurons: implications for Alzheimer's disease. [15644984] J Psychiatry Neurosci 29(6): 427-41 (2004)
2003 86	Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer's disease. [12587847] J Psychiatry Neurosci 28(1): 13-26 (2003)
2009 87	Use of Alzheimer disease biomarkers: potentially yes for clinical trials but not yet for clinical practice. [19622825] JAMA 302(4): 436-7 (2009)
2003 88	Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. [12517232] JAMA 289(2): 210-6 (2003)
2005 89	Current concepts in therapeutic strategies targeting cognitive decline and disease modification in Alzheimer's disease. [16489369] NeuroRx 2(4): 612-26 (2005)
2004 90	Biomarkers of Alzheimer disease in plasma. [15717023] NeuroRx 1(2): 226-34 (2004)
2004 91	Cerebrospinal fluid protein biomarkers for Alzheimer's disease. [15717022] NeuroRx 1(2): 213-25 (2004)
2004 92	Molecular neuroimaging in Alzheimer's disease. [15717021] NeuroRx 1(2): 206-12 (2004)
2004 93	Quantitative magnetic resonance techniques as surrogate markers of Alzheimer's disease. [15717020] NeuroRx 1(2): 196-205 (2004)
2004 94	Neuroprotective strategies in Alzheimer's disease. [15717012] NeuroRx 1(1): 117-27 (2004)
1992 95	Alzheimer's disease. [1437948] Postgrad Med J 68(801): 528-32 (1992)
2002 96	Alzheimer disease as a vascular disorder: nosological evidence. [11935076] Stroke 33(4): 1152-62 (2002)
2004 97	Alzheimer's disease: neuropathologic findings and recent advances in imaging. [14684506] AJR Am J Roentgenol 182(1): 3-13 (2004)
2002 98	Brain perfusion follow-up in Alzheimer's patients during treatment with acetylcholinesterase inhibitors. [12163621] J Nucl Med 43(8): 983-90 (2002)
2008 99	Diagnosis and treatment of dementia: 6. Management of severe Alzheimer disease. [19047609] CMAJ 179(12): 1279-87 (2008)
2003 100	Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. [12975222] CMAJ 169(6): 557-64 (2003)
2000 101	Causes of Alzheimer's disease. [11216203] CMAJ 162(1): 65-72 (2000)
2009 102	Fluorodeoxyglucose-positron-emission tomography, single-photon emission tomography, and structural MR imaging for prediction of rapid conversion to Alzheimer disease in patients with mild cognitive impairment: a meta-analysis. [19001534] AJNR Am J Neuroradiol 30(2): 404-10 (2009)
2008 103	Neuropathology for the neuroradiologist: plaques and tangles. [17925367] AJNR Am J Neuroradiol 29(1): 18-22 (2008)
2010 104	Amyloid-modifying therapies for Alzheimer's disease: therapeutic progress and its implications. [20640545] Age (Dordr) 32(3): 365-84 (2010)
2011 105	Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. [21211070] Alzheimers Res Ther 3(1): 1 (2011)
2011 106	The β-secretase enzyme BACE1 as a therapeutic target for Alzheimer's disease. [21639952] Alzheimers Res Ther 3(3): 20 (2011)
2010 107	Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy. [20122289] Alzheimers Res Ther 2(1): 1 (2010)
2009 108	Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease. [19845950] Alzheimers Res Ther 1(2): 7 (2009)
2009 109	Cerebral amyloid angiopathy in the aetiology and immunotherapy of Alzheimer disease. [19822028] Alzheimers Res Ther 1(2): 6 (2009)
2009 110	Drug development for Alzheimer's disease: where are we now and where are we headed? [19616185] Am J Geriatr Pharmacother 7(3): 167-85 (2009)
2011 111	[Guidelines for the medical treatment of patients with Alzheimer's disease]. [21739387] Acta Neurol Taiwan 20(2): 85-100 (2011)
2010 112	Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease. [20652578] Acta Neuropathol 120(3): 385-99 (2010)
2010 113	The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia. [20563819] Acta Neuropathol 120(2): 131-43 (2010)
2010 114	Intraneuronal beta-amyloid accumulation and synapse pathology in Alzheimer's disease. [20354705] Acta Neuropathol 119(5): 523-41 (2010)
2011 115	Alzheimer's disease is not "brain aging": neuropathological, genetic, and epidemiological human studies. [21516511] Acta Neuropathol 121(5): 571-87 (2011)
2008 116	TAR DNA-binding protein-43 in amyotrophic lateral sclerosis, frontotemporal lobar degeneration, and Alzheimer disease. [18575875] Acta Neuropathol 116(2): 135-40 (2008)
2008 117	Alzheimer disease models and human neuropathology: similarities and differences. [18038275] Acta Neuropathol 115(1): 5-38 (2008)
2011 118	Amyloid precursor protein processing and Alzheimer's disease. [21456963] Annu Rev Neurosci 34(-): 185-204 (2011)
2010 119	Initial experience in using continuous arterial spin-labeled MR imaging for early detection of Alzheimer disease. [20075093] AJNR Am J Neuroradiol 31(5): 847-55 (2010)
2011 120	Alzheimer's disease: a review of recent developments. [21691010] Ann Afr Med 10(2): 73-9 (2011)
2008 121	Neurobiology of apathy in Alzheimer's disease. [18641892] Arq Neuropsiquiatr 66(2B): 436-43 (2008)
2010 122	Alzheimer's disease: the pros and cons of pharmaceutical, nutritional, botanical, and stimulatory therapies, with a discussion of treatment strategies from the perspective of patients and practitioners. [21155625] Altern Med Rev 15(3): 223-44 (2010)
2008 123	Alzheimer's disease, amnestic mild cognitive impairment, and age-associated memory impairment: current understanding and progress toward integrative prevention. [18590347] Altern Med Rev 13(2): 85-115 (2008)
2004 124	Niemann-Pick Type C disease and Alzheimer's disease: the APP-endosome connection fattens up. [14982829] Am J Pathol 164(3): 757-61 (2004)
2009 125	Potential role of estrogen in the pathobiology and prevention of Alzheimer's disease. [19956426] Am J Transl Res 1(2): 131-47 (2009)
2010 126	Roles for dysfunctional sphingolipid metabolism in Alzheimer's disease neuropathogenesis. [20452460] Biochim Biophys Acta 1801(8): 878-86 (2010)
2010 127	Murine models of Alzheimer's disease and their use in developing immunotherapies. [20471477] Biochim Biophys Acta 1802(10): 847-59 (2010)
2010 128	Membrane rafts in Alzheimer's disease beta-amyloid production. [20303415] Biochim Biophys Acta 1801(8): 860-7 (2010)
2010 129	Intracellular cholesterol homeostasis and amyloid precursor protein processing. [20304094] Biochim Biophys Acta 1801(8): 853-9 (2010)
2010 130	Direct binding of cholesterol to the amyloid precursor protein: An important interaction in lipid-Alzheimer's disease relationships? [20304095] Biochim Biophys Acta 1801(8): 975-82 (2010)
2010 131	Mitochondrial trafficking of APP and alpha synuclein: Relevance to mitochondrial dysfunction in Alzheimer's and Parkinson's diseases. [19619643] Biochim Biophys Acta 1802(1): 11-9 (2010)
2010 132	Involvements of the lipid peroxidation product, HNE, in the pathogenesis and progression of Alzheimer's disease. [20176130] Biochim Biophys Acta 1801(8): 924-9 (2010)
2007 133	Amyloid beta ion channel: 3D structure and relevance to amyloid channel paradigm. [17553456] Biochim Biophys Acta 1768(8): 1966-75 (2007)
2007 134	Dysfunction of amyloid precursor protein signaling in neurons leads to DNA synthesis and apoptosis. [17113271] Biochim Biophys Acta 1772(4): 430-7 (2007)
2007 135	Focal adhesions regulate Abeta signaling and cell death in Alzheimer's disease. [17215111] Biochim Biophys Acta 1772(4): 438-45 (2007)
2007 136	Pin1 in Alzheimer's disease: multiple substrates, one regulatory mechanism? [17317113] Biochim Biophys Acta 1772(4): 422-9 (2007)
2009 137	Relevance of transgenic mouse models to human Alzheimer disease. [18948253] J Biol Chem 284(10): 6033-7 (2009)
2009 138	Understanding the association of apolipoprotein E4 with Alzheimer disease: clues from its structure. [18948255] J Biol Chem 284(10): 6027-31 (2009)
2010 139	Nonpharmacological therapies in Alzheimer's disease: a systematic review of efficacy. [20838046] Dement Geriatr Cogn Disord 30(2): 161-78 (2010)
2008 140	Cognitive performance and plasma levels of homocysteine, vitamin B12, folate and lipids in patients with Alzheimer disease. [18931498] Dement Geriatr Cogn Disord 26(4): 384-90 (2008)
2011 141	Modes of Aβ toxicity in Alzheimer's disease. [21706148] Cell Mol Life Sci 68(20): 3359-75 (2011)
2010 142	Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process. [20393191] Physiol Rev 90(2): 465-94 (2010)
2009 143	Reassessing the amyloid cascade hypothesis of Alzheimer's disease. [19124085] Int J Biochem Cell Biol 41(6): 1261-8 (2009)
2004 144	Contribution of cerebral amyloid angiopathy to Alzheimer's disease. [14707293] J Neurol Neurosurg Psychiatry 75(1): 1-4 (2004)
2007 145	Neuropsychological deficits in frontotemporal dementia and Alzheimer's disease: a meta-analytic review. [17371908] J Neurol Neurosurg Psychiatry 78(9): 917-28 (2007)
2010 146	Amyloid-independent mechanisms in Alzheimer's disease pathogenesis. [21068297] J Neurosci 30(45): 14946-54 (2010)
2010 147	Quantitative structural MRI for early detection of Alzheimer's disease. [20977326] Expert Rev Neurother 10(11): 1675-88 (2010)
2010 148	Causes versus effects: the increasing complexities of Alzheimer's disease pathogenesis. [20420489] Expert Rev Neurother 10(5): 683-91 (2010)
2004 149	Donepezil (Aricept) for treatment of Alzheimer's disease and other dementing conditions. [15853610] Expert Rev Neurother 4(1): 5-16 (2004)
2008 150	Gamma-secretase modulators: hopes and setbacks for the future of Alzheimer's treatment. [18986229] Expert Rev Neurother 8(11): 1611-3 (2008)
2008 151	Targeting miRNAs in Alzheimer's disease. [18986230] Expert Rev Neurother 8(11): 1615-6 (2008)
2008 152	Cystatin C: a potential target for Alzheimer's treatment. [18457524] Expert Rev Neurother 8(5): 687-9 (2008)
2009 153	All-trans retinoic acid as a novel therapeutic strategy for Alzheimer's disease. [19903021] Expert Rev Neurother 9(11): 1615-21 (2009)
2010 154	The biochemical study on the etiology of Alzheimer's disease. [20075608] Proc Jpn Acad Ser B Phys Biol Sci 86(1): 54-61 (2010)
2010 155	Current status on Alzheimer disease molecular genetics: from past, to present, to future. [20388643] Hum Mol Genet 19(R1): R4-R11 (2010)
2010 156	Molecular mechanisms of neurodegeneration in Alzheimer's disease. [20413653] Hum Mol Genet 19(R1): R12-20 (2010)
2010 157	Galantamine-ER for the treatment of mild-to-moderate Alzheimer's disease. [20169037] Clin Interv Aging 5(-): 1-6 (2010)
2008 158	Management of psychosis in patients with Alzheimer's disease: focus on aripiprazole. [18982919] Clin Interv Aging 3(3): 491-501 (2008)
2011 159	Recent progress in understanding Alzheimer's β-amyloid structures. [21411326] Trends Biochem Sci 36(6): 338-45 (2011)
2010 160	Alzheimer's disease: insights from Drosophila melanogaster models. [20036556] Trends Biochem Sci 35(4): 228-35 (2010)
2008 161	Androgen regulation of beta-amyloid protein and the risk of Alzheimer's disease. [17658612] Brain Res Rev 57(2): 444-53 (2008)
2008 162	Novel therapeutics for Alzheimer's disease. [18625448] Neurotherapeutics 5(3): 377-80 (2008)
2008 163	Measuring target effect of proposed disease-modifying therapies in Alzheimer's disease. [18625449] Neurotherapeutics 5(3): 381-90 (2008)
2008 164	Inhibition and modulation of gamma-secretase for Alzheimer's disease. [18625450] Neurotherapeutics 5(3): 391-8 (2008)
2008 165	beta-Secretase as a therapeutic target for Alzheimer's disease. [18625451] Neurotherapeutics 5(3): 399-408 (2008)
2008 166	New therapeutic targets in the neurovascular pathway in Alzheimer's disease. [18625452] Neurotherapeutics 5(3): 409-14 (2008)
2008 167	Therapeutics for Alzheimer's disease based on the metal hypothesis. [18625454] Neurotherapeutics 5(3): 421-32 (2008)
2008 168	Mouse models of Alzheimer's dementia: current concepts and new trends. [18818286] Endocrinology 149(12): 5952-7 (2008)
2012 169	Endoplasmic reticulum stress-induced CHOP activation mediates the down-regulation of leptin in human neuroblastoma SH-SY5Y cells treated with the oxysterol 27-hydroxycholesterol. [21983012] Cell Signal 24(2): 484-92 (2012)
2007 170	Roles of amyloid beta-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment. [17664130] Free Radic Biol Med 43(5): 658-77 (2007)
2008 171	Free radical-mediated damage to brain in Alzheimer's disease and its transgenic mouse models. [18482592] Free Radic Biol Med 45(3): 219-30 (2008)
2009 172	Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. [19339974] Nat Rev Neurosci 10(5): 333-44 (2009)
2011 173	New diagnostic criteria for Alzheimer's disease. [21861660] Biomark Med 5(4): 407-9 (2011)
2011 174	Role of amyloid β1-42 and neuroimaging biomarkers in Alzheimer's disease. [21861661] Biomark Med 5(4): 411-3 (2011)
2011 175	Delineating Alzheimer's disease progression with MGAT3, a biomarker for improved prognosis and personalized therapy. [22003913] Biomark Med 5(5): 645-7 (2011)
2010 176	Cerebrospinal fluid biomarkers of Alzheimer's disease. [20361010] Biomark Med 4(1): 51-63 (2010)
2010 177	Biomarkers of oxidative damage and inflammation in Alzheimer's disease. [20383271] Biomark Med 4(1): 27-36 (2010)
2010 178	Alzheimer's prevention initiative: a proposal to evaluate presymptomatic treatments as quickly as possible. [20383319] Biomark Med 4(1): 3-14 (2010)
2010 179	Biomarkers in Alzheimer's disease: past, present and future. [20387301] Biomark Med 4(1): 15-26 (2010)
2010 180	Blood-based biomarkers of Alzheimer's disease: challenging but feasible. [20387303] Biomark Med 4(1): 65-79 (2010)
2009 181	Alzheimer's mechanisms in ischemic brain degeneration. [19943340] Anat Rec (Hoboken) 292(12): 1863-81 (2009)
2009 182	In vivo morphological changes in animal models of amyotrophic lateral sclerosis and Alzheimer's-like disease: MRI approach. [19943341] Anat Rec (Hoboken) 292(12): 1882-92 (2009)
2010 183	3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the treatment of central nervous system diseases. [20837848] Arch Neurol 67(9): 1062-7 (2010)
2010 184	Beclin 1 complex in autophagy and Alzheimer disease. [20937944] Arch Neurol 67(10): 1181-4 (2010)
2009 185	Cellular prion protein mediates the toxicity of beta-amyloid oligomers: implications for Alzheimer disease. [19901162] Arch Neurol 66(11): 1325-8 (2009)
2009 186	Alzheimer abnormalities of the amygdala with Klüver-Bucy syndrome symptoms: an amygdaloid variant of Alzheimer disease. [19139311] Arch Neurol 66(1): 125-9 (2009)
2010 187	Alzheimer disease: update on basic mechanisms. [20926741] J Am Osteopath Assoc 110(9 Suppl 8): S3-9 (2010)
2010 188	Investigational medications for treatment of patients with Alzheimer disease. [20926740] J Am Osteopath Assoc 110(9 Suppl 8): S27-36 (2010)
2010 189	Current treatments for patients with Alzheimer disease. [20926739] J Am Osteopath Assoc 110(9 Suppl 8): S16-26 (2010)
2010 190	Biomarkers for early detection of Alzheimer disease. [20926738] J Am Osteopath Assoc 110(9 Suppl 8): S10-5 (2010)
2011 191	Disease-modifying treatments for Alzheimer's disease. [21765871] Ther Adv Neurol Disord 4(4): 203-16 (2011)
2010 192	Anti-amyloidogenic and anti-apoptotic role of melatonin in Alzheimer disease. [21358971] Curr Neuropharmacol 8(3): 211-7 (2010)
2010 193	Update on the pharmacological treatment of Alzheimer's disease. [20808547] Curr Neuropharmacol 8(1): 69-80 (2010)
2009 194	Implication of complement system and its regulators in Alzheimer's disease. [19721814] Curr Neuropharmacol 7(1): 1-8 (2009)
2007 195	Current experimental therapy for Alzheimer's disease. [18615180] Curr Neuropharmacol 5(2): 127-34 (2007)
2010 196	Convergence of amyloid-beta and tau pathologies on mitochondria in vivo. [20217279] Mol Neurobiol 41(2-3): 107-14 (2010)
2010 197	Microglia activation and anti-inflammatory regulation in Alzheimer's disease. [20195797] Mol Neurobiol 41(2-3): 115-28 (2010)
2010 198	Targeting NADPH oxidase and phospholipases A2 in Alzheimer's disease. [20195796] Mol Neurobiol 41(2-3): 73-86 (2010)
2010 199	Abnormal mitochondrial dynamics--a novel therapeutic target for Alzheimer's disease? [20101529] Mol Neurobiol 41(2-3): 87-96 (2010)
2010 200	The pathogenic implication of abnormal interaction between apolipoprotein E isoforms, amyloid-beta peptides, and sulfatides in Alzheimer's disease. [20052565] Mol Neurobiol 41(2-3): 97-106 (2010)
2011 201	Mitochondrial quality control and Parkinson's disease: a pathway unfolds. [21120708] Mol Neurobiol 43(2): 80-6 (2011)
2010 202	Why pleiotropic interventions are needed for Alzheimer's disease. [20437209] Mol Neurobiol 41(2-3): 392-409 (2010)
2009 203	Alzheimer's disease and blood-brain barrier function-Why have anti-beta-amyloid therapies failed to prevent dementia progression? [19481107] Neurosci Biobehav Rev 33(7): 1099-108 (2009)
2008 204	Alpha7 nicotinic acetylcholine receptor: a link between inflammation and neurodegeneration. [18180036] Neurosci Biobehav Rev 32(4): 693-706 (2008)
2010 205	Inhibition of BACE1 for therapeutic use in Alzheimer's disease. [20661410] Int J Clin Exp Pathol 3(6): 618-28 (2010)
2010 206	Alzheimer's disease: diverse aspects of mitochondrial malfunctioning. [20661404] Int J Clin Exp Pathol 3(6): 570-81 (2010)
2008 207	Tissue transglutaminase, protein cross-linking and Alzheimer's disease: review and views. [18784819] Int J Clin Exp Pathol 1(1): 5-18 (2008)
2010 208	Development of an efficient therapeutic agent for Alzheimer's disease: design and synthesis of dual inhibitors of acetylcholinesterase and serotonin transporter. [20190429] Chem Pharm Bull (Tokyo) 58(3): 273-87 (2010)
2010 209	Blood-based biomarkers of microvascular pathology in Alzheimer's disease. [19782124] Exp Gerontol 45(1): 75-9 (2010)
2010 210	Total and phosphorylated tau protein as biological markers of Alzheimer's disease. [19853650] Exp Gerontol 45(1): 30-40 (2010)
2010 211	Biomarkers of inflammation and amyloid-beta phagocytosis in patients at risk of Alzheimer disease. [19699791] Exp Gerontol 45(1): 57-63 (2010)
2010 212	Inflammation and anti-inflammatory strategies for Alzheimer's disease--a mini-review. [19752507] Gerontology 56(1): 3-14 (2010)
2010 213	Relationship between tau pathology and neuroinflammation in Alzheimer's disease. [20101714] Mt Sinai J Med 77(1): 50-8 (2010)
2010 214	Current treatment and recent clinical research in Alzheimer's disease. [20101716] Mt Sinai J Med 77(1): 3-16 (2010)
2010 215	Role of vascular risk factors and vascular dysfunction in Alzheimer's disease. [20101718] Mt Sinai J Med 77(1): 82-102 (2010)
2010 216	Vaccination as a therapeutic approach to Alzheimer's disease. [20101719] Mt Sinai J Med 77(1): 17-31 (2010)
2010 217	Neuropathology of Alzheimer's disease. [20101720] Mt Sinai J Med 77(1): 32-42 (2010)
2010 218	Transgenic mouse models of Alzheimer's disease. [20101721] Mt Sinai J Med 77(1): 69-81 (2010)
2010 219	Cell "self-eating" (autophagy) mechanism in Alzheimer's disease. [20101724] Mt Sinai J Med 77(1): 59-68 (2010)
2010 220	Immunization therapy for Alzheimer disease: a comprehensive review of active immunization strategies. [20139660] Tohoku J Exp Med 220(2): 95-106 (2010)
2010 221	Novel therapeutics for Alzheimer's disease: an update. [20205057] Curr Opin Drug Discov Devel 13(2): 235-46 (2010)
2008 222	Aluminum as a risk factor for Alzheimer's disease. [18392545] Rev Lat Am Enfermagem 16(1): 151-7 (2008)
2011 223	Neurovascular dysfunction, inflammation and endothelial activation: implications for the pathogenesis of Alzheimer's disease. [21439035] J Neuroinflammation 8(-): 26 (2011)
2011 224	Alzheimer's disease - a neurospirochetosis. Analysis of the evidence following Koch's and Hill's criteria. [21816039] J Neuroinflammation 8(-): 90 (2011)
2008 225	Interactions between APP secretases and inflammatory mediators. [18564425] J Neuroinflammation 5(-): 25 (2008)
2008 226	Alzheimer disease pathology as a host response. [18520771] J Neuropathol Exp Neurol 67(6): 523-31 (2008)
2010 227	Genetics and biology of Alzheimer's disease and frontotemporal lobar degeneration. [20607039] Int J Clin Exp Med 3(2): 129-43 (2010)
2008 228	Antioxidant therapy in Alzheimer's disease: theory and practice. [18991755] Mini Rev Med Chem 8(13): 1395-406 (2008)
2009 229	Diffusion tensor imaging in Alzheimer's disease and mild cognitive impairment. [19847044] Behav Neurol 21(1): 39-49 (2009)
2009 230	Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo. [19847050] Behav Neurol 21(1): 117-28 (2009)
2011 231	The Interface between Cytoskeletal Aberrations and Mitochondrial Dysfunction in Alzheimer's Disease and Related Disorders. [22110363] Exp Neurobiol 20(2): 67-80 (2011)
2008 232	Developing new treatments for Alzheimer's disease: the who, what, when, and how of biomarker-guided therapies. [18498669] Int Psychogeriatr 20(5): 871-89 (2008)
2005 233	Very early detection of Alzheimer neuropathology and the role of brain reserve in modifying its clinical expression. [16306243] J Geriatr Psychiatry Neurol 18(4): 218-23 (2005)
2010 234	Sequence variation in SORL1 and dementia risk in Swedes. [19653016] Neurogenetics 11(1): 139-42 (2010)
2009 235	Genetic aspects of Alzheimer disease. [19276785] Neurologist 15(2): 80-6 (2009)
2008 236	Biomarkers for early detection of Alzheimer pathology. [18097155] Neurosignals 16(1): 11-8 (2008)
2005 237	Stress in the brain: novel cellular mechanisms of injury linked to Alzheimer's disease. [15960984] Brain Res Brain Res Rev 49(1): 1-21 (2005)
2007 238	Mechanisms of disease: new therapeutic strategies for Alzheimer's disease--targeting APP processing in lipid rafts. [17611486] Nat Clin Pract Neurol 3(7): 374-82 (2007)
2009 239	Cell cycle re-entry mediated neurodegeneration and its treatment role in the pathogenesis of Alzheimer's disease. [19114068] Neurochem Int 54(2): 84-8 (2009)
2010 240	Early detection of Alzheimer's disease with PET imaging. [20197691] Neurodegener Dis 7(1-3): 131-5 (2010)
2010 241	Alzheimer disease. [20831921] Dis Mon 56(9): 484-546 (2010)
2010 242	Biological markers of amyloid beta-related mechanisms in Alzheimer's disease. [19815015] Exp Neurol 223(2): 334-46 (2010)
2010 243	Signaling effect of amyloid-beta(42) on the processing of AbetaPP. [19747481] Exp Neurol 221(1): 18-25 (2010)
2010 244	Alzheimer's disease and tauopathy studies in flies and worms. [20302939] Neurobiol Dis 40(1): 21-8 (2010)
2009 245	Biomarkers of Alzheimer's disease. [19010417] Neurobiol Dis 35(2): 128-40 (2009)
2010 246	Probing the biology of Alzheimer's disease in mice. [20547123] Neuron 66(5): 631-45 (2010)
2010 247	Biomarkers in translational research of Alzheimer's disease. [20394760] Neuropharmacology 59(4-5): 310-22 (2010)
2007 248	Use of functional magnetic resonance imaging in the early identification of Alzheimer's disease. [17476598] Neuropsychol Rev 17(2): 127-43 (2007)
2008 249	Neuropsychological contributions to the early identification of Alzheimer's disease. [18347989] Neuropsychol Rev 18(1): 73-90 (2008)
2008 250	Defining "prodromal" Alzheimer's disease, frontotemporal dementia, and Lewy body dementia: are we there yet? [18327642] Neuropsychol Rev 18(1): 70-2 (2008)
2010 251	Alzheimer's disease and neuronal network activity. [19885650] Neuromolecular Med 12(1): 44-7 (2010)
2010 252	Adverse stress, hippocampal networks, and Alzheimer's disease. [19943124] Neuromolecular Med 12(1): 56-70 (2010)
2010 253	Functional alterations in memory networks in early Alzheimer's disease. [20069392] Neuromolecular Med 12(1): 27-43 (2010)
2010 254	An overview of APP processing enzymes and products. [20232515] Neuromolecular Med 12(1): 1-12 (2010)
2005 255	Transgenic models of Alzheimer's disease: learning from animals. [16389306] NeuroRx 2(3): 423-37 (2005)
2005 256	APP23 mice as a model of Alzheimer's disease: an example of a transgenic approach to modeling a CNS disorder. [15744222] CNS Spectr 10(3): 207-22 (2005)
2009 257	Role of mitochondria in neurodegenerative diseases: mitochondria as a therapeutic target in Alzheimer's disease. [19890241] CNS Spectr 14(8 Suppl 7): 8-13; discussion 16-8 (2009)
2010 258	Discovery of notch-sparing gamma-secretase inhibitors. [20088802] Curr Alzheimer Res 7(3): 207-9 (2010)
2009 259	Towards retinoid therapy for Alzheimer's disease. [19519313] Curr Alzheimer Res 6(3): 302-11 (2009)
2008 260	Gamma-secretase inhibition and modulation for Alzheimer's disease. [18393800] Curr Alzheimer Res 5(2): 158-64 (2008)
2008 261	Assembly, maturation, and trafficking of the gamma-secretase complex in Alzheimer's disease. [18393798] Curr Alzheimer Res 5(2): 132-46 (2008)
2008 262	Structure-function relationships of pre-fibrillar protein assemblies in Alzheimer's disease and related disorders. [18537546] Curr Alzheimer Res 5(3): 319-41 (2008)
2008 263	The neuronal sortilin-related receptor gene SORL1 and late-onset Alzheimer's disease. [18713574] Curr Neurol Neurosci Rep 8(5): 384-91 (2008)
2009 264	Update on amyloid imaging: from healthy aging to Alzheimer's disease. [19664363] Curr Neurol Neurosci Rep 9(5): 345-52 (2009)
2009 265	Mapping brain beta-amyloid. [19478666] Curr Opin Neurol 22(4): 356-61 (2009)
2011 266	Antiretroviral medications disrupt microglial phagocytosis of β-amyloid and increase its production by neurons: implications for HIV-associated neurocognitive disorders. [21649911] Mol Brain 4(1): 23 (2011)
2011 267	APP processing in Alzheimer's disease. [21214928] Mol Brain 4(-): 3 (2011)
2010 268	Presenilins and the gamma-secretase: still a complex problem. [20181106] Mol Brain 3(-): 7 (2010)
2011 269	Biology and pathophysiology of the amyloid precursor protein. [21527012] Mol Neurodegener 6(1): 27 (2011)
2011 270	Gene expression endophenotypes: a novel approach for gene discovery in Alzheimer's disease. [21569597] Mol Neurodegener 6(-): 31 (2011)
2007 271	The Alzheimer's disease beta-secretase enzyme, BACE1. [18005427] Mol Neurodegener 2(-): 22 (2007)
2011 272	Biomarkers in Alzheimer's disease. [21808632] Front Neurol 2(-): 46 (2011)
2011 273	Biomarkers predicting Alzheimer's disease in cognitively normal aging. [21779293] J Clin Neurol 7(2): 60-8 (2011)
2010 274	The clinical use of structural MRI in Alzheimer disease. [20139996] Nat Rev Neurol 6(2): 67-77 (2010)
2010 275	The secretases: enzymes with therapeutic potential in Alzheimer disease. [20139999] Nat Rev Neurol 6(2): 99-107 (2010)
2005 276	Genetic mouse models of Alzheimer's disease. [16444901] Neural Plast 12(4): 299-310 (2005)
2007 277	The role of presenilin and its interacting proteins in the biogenesis of Alzheimer's beta amyloid. [16944319] Neurochem Res 32(4-5): 609-23 (2007)
2007 278	Alzheimer's disease and mild cognitive impairment. [17659182] Neurol Clin 25(3): 577-609, v (2007)
2007 279	An update on the amyloid hypothesis. [17659184] Neurol Clin 25(3): 669-82, vi (2007)
2010 280	Abeta DNA vaccination for Alzheimer's disease: focus on disease prevention. [20205639] CNS Neurol Disord Drug Targets 9(2): 207-16 (2010)
2010 281	Amyloid-beta immunotherapy for Alzheimer's disease. [20205640] CNS Neurol Disord Drug Targets 9(2): 197-206 (2010)
2009 282	Immunotherapy, vascular pathology, and microhemorrhages in transgenic mice. [19275636] CNS Neurol Disord Drug Targets 8(1): 50-64 (2009)
2009 283	Antibody responses, amyloid-beta peptide remnants and clinical effects of AN-1792 immunization in patients with AD in an interrupted trial. [19355930] CNS Neurol Disord Drug Targets 8(2): 88-97 (2009)
2009 284	Alternative Abeta immunotherapy approaches for Alzheimer's disease. [19355932] CNS Neurol Disord Drug Targets 8(2): 114-27 (2009)
2008 285	Beta-secretase: structure, function, and evolution. [18673212] CNS Neurol Disord Drug Targets 7(3): 278-94 (2008)
2011 286	Combined Imaging Markers Dissociate Alzheimer's Disease and Frontotemporal Lobar Degeneration - An ALE Meta-Analysis. [21811457] Front Aging Neurosci 3(-): 10 (2011)
2010 287	Staging anti-inflammatory therapy in Alzheimer's disease. [21152343] Front Aging Neurosci 2(-): 142 (2010)
2010 288	Intracellular accumulation of amyloid-Beta - a predictor for synaptic dysfunction and neuron loss in Alzheimer's disease. [20552046] Front Aging Neurosci 2(-): 8 (2010)
2010 289	Presenilin/gamma-Secretase and Inflammation. [20559464] Front Aging Neurosci 2(-): 16 (2010)
2011 290	Membrane Incorporation, Channel Formation, and Disruption of Calcium Homeostasis by Alzheimer's β-Amyloid Protein. [21547225] Int J Alzheimers Dis 2011(-): 304583 (2011)
2011 291	The apolipoprotein e antagonistic pleiotropy hypothesis: review and recommendations. [21423560] Int J Alzheimers Dis 2011(-): 726197 (2011)
2011 292	Amyloid oligomer neurotoxicity, calcium dysregulation, and lipid rafts. [21331330] Int J Alzheimers Dis 2011(-): 906964 (2011)
2011 293	Detection of Soluble Amyloid-β Oligomers and Insoluble High-Molecular-Weight Particles in CSF: Development of Methods with Potential for Diagnosis and Therapy Monitoring of Alzheimer's Disease. [22114742] Int J Alzheimers Dis 2011(-): 151645 (2011)
2011 294	Utilization of APPswe/PS1dE9 Transgenic Mice in Research of Alzheimer's Disease: Focus on Gene Therapy and Cell-Based Therapy Applications. [22114743] Int J Alzheimers Dis 2011(-): 517160 (2011)
2008 295	Targeting the endocannabinoid system in Alzheimer's disease. [18997302] J Alzheimers Dis 15(3): 495-504 (2008)
2010 296	A synergistic dysfunction of mitochondrial fission/fusion dynamics and mitophagy in Alzheimer's disease. [20463393] J Alzheimers Dis 20 Suppl 2(-): S401-12 (2010)
2010 297	Neuropathologic alterations in mild cognitive impairment: a review. [20061641] J Alzheimers Dis 19(1): 221-8 (2010)
2010 298	Alzheimer's disease and the amyloid-beta peptide. [20061647] J Alzheimers Dis 19(1): 311-23 (2010)
2008 299	Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies. [18953105] J Alzheimers Dis 15(2): 157-68 (2008)
2008 300	Chronic inflammation and amyloidogenesis in Alzheimer's disease -- role of Spirochetes. [18487847] J Alzheimers Dis 13(4): 381-91 (2008)
2008 301	The irreversible binding of amyloid peptide substrates to insulin-degrading enzyme: a biological perspective. [19098445] Prion 2(2): 51-6 (2008)
2009 302	Prion protein and Alzheimer disease. [19887909] Prion 3(4): 190-4 (2009)
2010 303	Epigenetic modification is linked to Alzheimer's disease: is it a maker or a marker? [21034526] BMB Rep 43(10): 649-55 (2010)
2011 304	Biomarkers in Alzheimer's disease. [21303300] Clin Chem Lab Med 49(5): 773-8 (2011)
2009 305	Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. [19829371] Nature 461(7266): 916-22 (2009)
2010 306	Bapineuzumab. [20497044] Expert Opin Biol Ther 10(7): 1121-30 (2010)
2010 307	Beta-amyloid oligomers and cellular prion protein in Alzheimer's disease. [19960174] J Mol Med (Berl) 88(4): 331-8 (2010)
2008 308	Catalytic antibodies to amyloid beta peptide in defense against Alzheimer disease. [18486927] Autoimmun Rev 7(5): 391-7 (2008)
2008 309	Copper binding to the Alzheimer's disease amyloid precursor protein. [18030462] Eur Biophys J 37(3): 269-79 (2008)
2009 310	Cytoskeletal pathologies of Alzheimer disease. [19479823] Cell Motil Cytoskeleton 66(8): 635-49 (2009)
2009 311	New strategies for Alzheimer's disease and cognitive impairment. [20716915] Oxid Med Cell Longev 2(5): 279-89 (2009)
2011 312	Identifying and validating biomarkers for Alzheimer's disease. [20971518] Trends Biotechnol 29(1): 26-32 (2011)
2008 313	Genetic aspects of Alzheimer disease. [18414205] Genet Med 10(4): 231-9 (2008)
2010 314	Genetics of Alzheimer disease. [21045163] J Geriatr Psychiatry Neurol 23(4): 213-27 (2010)
2010 315	Low-density lipoprotein receptor-related protein-1: a serial clearance homeostatic mechanism controlling Alzheimer's amyloid beta-peptide elimination from the brain. [20854368] J Neurochem 115(5): 1077-89 (2010)
2010 316	Yeast as a model for studying Alzheimer's disease. [20618869] FEMS Yeast Res 10(8): 961-9 (2010)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Fatal error: Uncaught Error: Call to undefined function mysql_connect() in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Alzheimer s disease.php:92 Stack trace: #0 {main} thrown in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Alzheimer s disease.php on line 92